Compare Crispr Therapeutics AG (CRSP) vs Caesars Entertainment Inc (CZR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Caesars Entertainment Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Caesars Entertainment Inc trades at $29.49 (market cap $6.02B). The key difference: Caesars Entertainment Inc is the larger of the two by market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Caesars Entertainment Inc for 31 Days on average.
| CRSP | CZR | |
|---|---|---|
Market Cap | $4.88B | $6.02B |
Volume | 2,861,747 | 6,412,151 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $30.41 |
52-Week Low | $44.34 | $18.14 |
Typical Hold Time | 77 Days | 31 Days |
Enterprise Value | $3.30B | $29.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
CZR trades at $29.50, up slightly by 0.03% today, with a bearish technical signal and neutral oscillators. The company reported a net loss of $502 million in 2025, missing earnings estimates for three consecutive quarters, while revenue remains stable near $11.5 billion. A pending merger with Fertitta Entertainment at $31.00 per share is under regulatory review, with several law firms investigating the deal's fairness.
CZR faces headwinds from persistent losses and high debt, but the merger offer provides a near-term price floor. Upside depends on operational turnaround and deal approval, while risks include earnings volatility and regulatory hurdles. Analyst consensus is mixed, with a hold-heavy rating and a $30.75 price target slightly above current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →
